| Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis R Romero, VI Sayin, SM Davidson, MR Bauer, SX Singh, SE LeBoeuf, ... Nature medicine 23 (11), 1362-1368, 2017 | 544 | 2017 |
| Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1 L Lignitto, SE LeBoeuf, H Homer, S Jiang, M Askenazi, TR Karakousi, ... Cell 178 (2), 316-329. e18, 2019 | 432 | 2019 |
| Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer VI Sayin, SE LeBoeuf, SX Singh, SM Davidson, D Biancur, BS Guzelhan, ... Elife 6, e28083, 2017 | 195 | 2017 |
| SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2 Q Lu, J Liu, S Zhao, MFG Castro, M Laurent-Rolle, J Dong, X Ran, ... Immunity 54 (6), 1304-1319. e9, 2021 | 135 | 2021 |
| Activation of oxidative stress response in cancer generates a druggable dependency on exogenous non-essential amino acids SE LeBoeuf, WL Wu, TR Karakousi, B Karadal, SRE Jackson, ... Cell metabolism 31 (2), 339-350. e4, 2020 | 119 | 2020 |
| Hyperactive CDK2 activity in basal-like breast cancer imposes a genome integrity liability that can be exploited by targeting DNA polymerase ε VO Sviderskiy, L Blumenberg, E Gorodetsky, TR Karakousi, N Hirsh, ... Molecular cell 80 (4), 682-698. e7, 2020 | 28 | 2020 |
| Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer M Ciampricotti, T Karakousi, AL Richards, À Quintanal-Villalonga, ... Cancer discovery 11 (12), 3214-3229, 2021 | 26 | 2021 |
| KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance AM Zavitsanou, R Pillai, Y Hao, WL Wu, E Bartnicki, T Karakousi, ... Cell reports 42 (11), 2023 | 14 | 2023 |
| Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer R Pillai, SE LeBoeuf, Y Hao, C New, JLE Blum, A Rashidfarrokhi, ... Science Advances 10 (13), eadm9859, 2024 | 6 | 2024 |
| Lymph node metastasis fuels systemic disease KS Ventre, T Karakousi, AW Lund Trends in Cancer 8 (8), 623-625, 2022 | 3 | 2022 |
| Uncovering metabolic bottlenecks in KEAP1 mutant lung cancer SE LeBoeuf, W Wu, T Karakousi, R Wild, T Papagiannakopoulos Cancer Res 80 (16 suppl), Abstract 2569, 2020 | 1 | 2020 |
| Lymphatic vessels in the age of cancer immunotherapy T Karakousi, T Mudianto, AW Lund Nature Reviews Cancer, 1-19, 2024 | | 2024 |
| Glutamine antagonist DRP-104 enhances anti-tumor responses in KEAP1 mutant lung cancer R Pillai, S LeBoeuf, A Rashidfarrokhi, SM Huang, T Karakousi, ... Cancer Research 83 (7_Supplement), 4904-4904, 2023 | | 2023 |
| Melanoma-shed, lymph-borne CSPG4 conditions the pre-metastatic lymph node niche H Bois, AL Chen, KS Ventre, MS Steele, T Karakousi, AW Lund Cancer Research 83 (7_Supplement), 3511-3511, 2023 | | 2023 |
| Sirpiglenastat (DRP-104), a novel broad acting glutamine antagonist, has therapeutic potential in targeting KEAP1-mutant lung cancer S LeBoeuf, R Pillai, SM Huang, T Karakousi, W Wu, V Sayin, R Wild, ... Cancer Research 82 (12_Supplement), 2174-2174, 2022 | | 2022 |
| LGG-07. Novel CRISPR/Cas9 induced KIAA1549: BRAF fusion model for preclinical studies of pediatric gliomas K Patel, G Zhao, SM Huang, T Karakousi, T Nicolaides, ... Neuro-oncology, 2022 | | 2022 |
| Rlf-Mycl1 gene fusion as a novel oncogenic driver in a mouse model of small cell lung cancer M Ciampricotti, T Karakousi, AQ Villalonga, V Allaj, A Ventura, T Sen, ... Cancer Research 80 (16_Supplement), 420-420, 2020 | | 2020 |
| Abstract A43: Loss of Keap1 promotes KRAS-driven lung cancer and results in genotype-specific vulnerabilities R Romero, VI Sayin, DM Shawn, M Bauer, SX Singh, S LeBoeuf, ... Cancer Research 78 (10_Supplement), A43-A43, 2018 | | 2018 |
| Loss of Keap1 promotes KRAS-driven lung cancer and results in genotype-specific vulnerabilities. R Romero, VI Sayin, DM Shawn, M Bauer, SX Singh, S LeBoeuf, ... CANCER RESEARCH 78 (10), 50-50, 2018 | | 2018 |
